RecruitingPhase 1NCT05764954

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

25 participants

Start Date

Aug 4, 2023

Study Type

INTERVENTIONAL

Conditions

Adenocarcinoma of Lung

Summary

The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.

Eligibility

Min Age: 22 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether tumor-treating fields (TTFields) — a non-invasive wearable device that delivers low-intensity electrical fields to disrupt cancer cell division — can be used before and after surgery in people with early-stage lung adenocarcinoma (a type of lung cancer). **You may be eligible if...** - You are 22 or older - You have early-stage lung adenocarcinoma (stages 1A2, 1A3, or IB) confirmed by biopsy, and you are eligible for surgical removal - You have a lung nodule over 1 cm that is suspected to be this type of lung cancer **You may NOT be eligible if...** - You have an active second cancer in the chest (unless treated and in remission for at least 5 years) - You have an implanted electronic device (like a pacemaker) that could interact with TTFields - You have a known allergy to gels used with the device - You are pregnant or may become pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.